transcutaneous vagus nerve stimulation (tVNS)

transcutaneous vagus nerve 
tVNS

3  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
improvement in heart failure functional class, quality of life, left ventricular ejection fraction and left ventricular end-systolic volume 12,13. We 14-18 and others 19 have recently shown that low level vagus nerve stimulation (LLVNS), at voltages substantially below the threshold for slowing the sinus rate or AV conduction, suppressed AF inducibility and decreased the duration of AF episodes that were induced by strong cholinergic stimulation. In those experiments, LLVNS applied to both vagal trunks dissected in the neck 14-16, to the right vagus nerve alone 18, or to the vagal preganglionic fibers at the posterior wall of the superior vena cava 17, exerted equally strong anti-arrhythmic effects.  The anti-inflammatory properties of the VN have been recently recognized 20,21. The cholinergic anti-inflammatory pathway can be activated experimentally by electrical VN stimulation to inhibit inflammatory cytokine production (including TNF-Ä®), prevent tissue injury and improve survival in multiple experimental models of systemic inflammation and sepsis 20-24. A substantial body of evidence suggests that AF and inflammatory pathways have a bidirectional relationship 25. Several studies suggested that inflammation may confer an increased risk of AF. In a large population-based study, CRP levels predicted both the presence of AF at baseline and the development of AF during follow-up, even after adjustment for other known cardiovascular risk factors, and the risk of AF was progressively higher with increasing CRP quartiles 26. In a recent experimental study, TNF-Ä® overexpressing mice developed spontaneous episodes of AF and were found to have electrophysiological and structural changes known to promote AF, including increased calcium transient and atrial fibrosis 27. Whether AF is the cause or the consequence of inflammation cannot be determined on the basis of the available evidence. Based on the observation that transcutaneous electrical stimulation of the tragus, the anterior protuberance of the outer ear, where the auricular branch of the vagus nerve is located, elicits evoked potentials in the brainstem in humans 28, we examined the effects of low-level tragus stimulation (LLTS) for inhibiting AF in a canine model of rapid atrial pacing 29. Notably, the anti-arrhythmic effects of LLTS were similar to those of LLVNS delivered to the cervical vagus nerve trunk 29. We recently translated these results into patients with drug-refractory AF undergoing AF ablation, and showed that LLTS for just one hour significantly shortened the AF duration, and suppressed inflammatory cytokines, indicating that neuromodulation by LLTS is a very promising, non-invasive therapy to treat AF and AF-related inflammation 30. Before these results can be translated into clinical practice, the long-term clinical efficacy of this approach needs to be shown in ambulatory patients with AF. It has been recently shown that transcutaneous VN stimulation applied for just 15 minutes in healthy volunteers increases heart rate variability (HRV) and reduces sympathetic nerve activity 31. In this study, we hypothesize that intermittent (1 hour daily) LLTS for 6 months may decrease AF burden and suppress inflammatory cytokines in patients with paroxysmal AF. These investigations will establish the first evidence of the long-term effects of LLTS on AF suppression in patients with paroxysmal AF and may provide the basis for a potential expansion of the therapeutic targets of this treatment modality beyond AF, into other inflammatory conditions, including atherosclerosis 32.    C. Preliminary studies 
4  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
LLTS suppresses AF in dogs: We studied the effects of transcutaneous electrical stimulation at the tragus for inhibiting AF. In 10 pentobarbital-anesthetized dogs, LLTS (20 Hz) in the right ear 
was accomplished by attaching two alligator clips onto the tragus. The voltage slowing the sinus rate was used as the threshold for setting the LLTS at 80% below threshold. The antiarrhythmic effects of LLTS were similar to those of LLVNS delivered to the cervical VN trunk (Figure 1A). In contrast, LLTS after transection of both VN failed to show any antiarrhythmic effect, indicating that the efferent VN are essential for its antiarrhythmic effects (Figure 1B). We concluded that LLTS can reverse RAP-induced atrial remodeling and inhibit AF inducibility, suggesting a potential non-invasive treatment for AF 29.  Neuromodulation suppresses AF and inflammation in humans: We have recently shown that transcutaneous electrical stimulation of the auricular branch of the vagus nerve at the tragus (low-level tragus stimulation; LLTS) in humans has antiarrhythmic and anti-inflammatory effects 30. Forty patients with paroxysmal AF who presented in sinus rhythm for AF ablation, were randomized to either 1 hour of LLTS (n=20) or control (n=20). LLTS in the right ear, 50% lower than the voltage that slowed the sinus rate, was accomplished by attaching a flat metal clip onto the tragus. Under general anesthesia, AF was induced at baseline and after 1 hour of LLTS or sham stimulation and were analyzed for inflammatory cytokines, LQFOXGLQJ71)Ä®DQG&53XVLQJDPXOWLSOH[LPPXQRDVVD\3DFLQJ-induced AF duration decreased significantly by 6.3Â±1.9 min compared to baseline in the LLTS group, but not in the control (p=0.002 for comparison between groups; Figure 2A). AF cycle length increased significantly from baseline by 28.8Â±6.5ms in the LLTS group, but not in the control (p=0.0002 for comparison between groups). Systemic (femoral vein) but not coronary sinus TNFÄ® and CRP levels decreased significantly only in the LLTS group (Figure 2B). Importantly, the magnitude of decrease in TNF-Ä® levels by LLTS was comparable with the difference between patients with active vs. inactive inflammatory diseases 33. We concluded that LLTS acutely suppresses AF and decreases inflammatory cytokines in patients with paroxysmal AF, supporting the emerging paradigm of  
 

5  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
neuromodulation to treat AF 30. The results of this study were published in the Journal of the American College of Cardiology 30.  D. Research design and Methods Specific Aim 1: To examine the effect of intermittent (1 hour daily) LLTS on AF burden in patients with paroxysmal AF over a 6-month period. This is a prospective double-blind randomized controlled study. Patients with paroxysmal AF, documented by ECG, pacemaker/implantable cardioverter defibrillator (ICD) electrogram or Holter monitor, within 3 months of randomization on 2 separate occasions, at least 1 day apart, of at least 30 seconds duration, will be eligible for inclusion in the study.  Patients will be excluded if they have any of the following: 1. Left ventricular dysfunction (Left ventricular ejection fraction <40%) 2. Significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant valvular diseases)  3. Recent (<6 months) stroke or myocardial infarction  4. Severe heart failure (NYHA IV) 5. Left atrial dilatation (>55mm) 6. Recurrent vaso-vagal syncopal episodes 7. Unilateral or bilateral vagotomy 8. Sick sinus syndrome, 2nd or 3rd degree AV block, bifascicular block or prolonged (PR>300ms) 1st degree AV block Patients will be recruited from the inpatient services and outpatient clinics of the University of Oklahoma Health Sciences Center. A meeting with all study personnel to review the study protocol will be held before initiation of the study, as well as every 3-6 months, depending on study progress. Informed consent will be obtained prior to enrollment in the study. The randomization schedule will be implemented with the use of concealed envelopes and it will be stratified by sex. Blocked randomization will be used to decrease the chance of imbalances in the two groups over time. After informed consent and screening procedures are completed, all patients will undergo noninvasive continuous ECG monitoring for 2 weeks to evaluate their AF burden (the percent of time spent in AF) using an adhesive waterproof continuous monitoring patch (ZioÂ® Patch). The ZioÂ® Patch (iRhythm Technologies, Inc) is an FDA approved, single-lead, lightweight, 14-day ambulatory ECG adhesive patch monitor. The patch is well tolerated and allows significantly longer continuous monitoring than a regular Holter monitor, leading to an improved AF detection rate 34. After the 2-week monitoring period, patients will be randomly assigned (1:1) to active or sham LLTS. Patients will be blinded to the treatment allocation, and every effort will be made to conceal from the study personnel the nature of the intervention in each study arm. Blinding of the patients will be accomplished by having a sham control arm, in which stimulation will be delivered to a different site (the ear lobe), devoid of vagal innervation 35. By doing so, all patients will be aware that they are receiving stimulation, but they will not be told which site achieves active VN 
transcutaneous

8  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
Specific Aim 2: To examine the effect of intermittent (1 hour daily) LLTS on inflammatory cytokines and their gene expression in patients with paroxysmal AF over a 6-month period. The same group assignment described in Aim 1 will be used for Aim 2. The importance of this Aim is highlighted by accumulating evidence that inflammation promotes the persistence of AF 25,41. Blood samples (10ml) will be collected at baseline and at 3 and 6 months for cytokine measurement. Samples will be centrifuged (4000g for 10 min), and serum will be stored in aliquots at -20Â°C until assayed. Patientsâ€™ serum will be saved frozen and processed in batches of 10 to 12. The investigators performing the cytokine assays will be blinded to group assignment. All assays will be run at the Humphrey Lab at OUHSC. Inflammatory cytokines, including TNF-Ä®, and IL-6, will be measured using commercially available immunoassays analyzed on a flow cytometer (multiplex assays). In addition, peripheral blood mononuclear cells (PBMCs) will be isolated using MACS magnetic bead purification. Inflammatory cytokine gene expression profile will be measured at the above time points, using commercially available microarrays. Finally, we will perform exploratory analyses in order to determine relationships between clinical and cytokine responses to LLTS and identify predictors of response based on baseline cytokine levels. It is known that vagus nerve stimulation attenuates inflammation through the cholinergic anti-inflammatory pathway 20-24. If this pathway is important in AF as well, we expect that the decrease in cytokines will be correlated with the anti-arrhythmic effect.   Duration of participation Enrolled patients will participate for a maximum of 7 months with 3 outpatient office visits at 1, 3 and 6 months. Patient enrollment A maximum of 52 patients meeting the inclusion criteria and not meeting the exclusion criteria will be enrolled in the study. The enrollment period is expected to last for at least 17 months, given that on average 30 patients with paroxysmal AF are seen in our clinics each month and assuming that 1 out of 4 eligible patients would agree to participate in the study.   Data collection and analysis The final data will be pooled and analyzed by the investigators.    E. Statistical methods The primary outcome of this study is the percent of time spent in AF over the monitoring period (AF burden) at the 6-month time point. Secondary outcomes include total duration of AF over the 2-week monitoring period, longest daily duration of AF, measures of HRV and serum cytokine levels. Outcomes will be compared between groups using a Generalized Estimating Equations modeling approach, with 3 time points (baseline, 3 months, 6 months) and 4 terms included in the model (group effect, time effect, group by time interaction, adjustment for baseline measure). 
9  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
Significant interactions will be followed by time trend analyses stratified by intervention group. If the interaction is not significant, the interaction term will be dropped from the model and the between-group comparisons will be made by combining the 3-month and 6-month data. For all pair-wise testing, we will adjust for multiple comparisons using Tukeyâ€™s method. The modeling assumptions will be evaluated by plotting the residuals by the predicted values (for the constant variance assumption) and comparing the normal QQ plot with the QQ plot of the residuals (for the normality assumption). If the modeling assumptions are not satisfied, we will perform a natural log transformation of the data, to better satisfy these assumptions. For 0 values, a value of 0.01 will be added to each measure before applying the natural log. Analyses will be based on the intention-to-treat principle. In post-hoc exploratory analyses, we will use logistic regression analysis to identify predictors of clinical and cytokine response to LLTS, defined as a decrease of AF burden and a decrease in cytokines at 6-month follow-up, respectively. Those variables that which are associated with response to LLTS in univariate analysis at p<0.1 will be entered into a multivariate logistic regression model, using a backward elimination method to identify the most parsimonious model. In light of the limited sample size, such analyses will be underpowered and will be considered hypothesis-generating only. Statistical significance will be declared at p<0.05.  Sample size and power calculations: For purposes of sample size calculations we have simplified the analysis to focus on the AF burden at the 6-month time point between the 2 groups. Assuming a meanÂ±standard deviation AF burden in the control group of 28.4Â±31.2% 34 and a 87% reduction in the LLTS group  to 3.7% (assuming a common standard deviation of 31.2%), 26 patients per group would provide 80% power to detect the specified effect sizes at a two-VLGHGVLJQLILFDQFHÄ®level of 0.05. Approximately 30 patients with paroxysmal AF are seen in our clinics each month. Assuming that 1 out of 4 eligible patients would agree to participate in the study, we should be able to enroll the required number of patients within the proposed 17 months, allowing for 6 months of additional follow up and a final month for data analysis.   F. Gender/Minority/Pediatric Inclusion for Research Participants will be age 21 or older. Race, minority status and gender will not affect enrollment. G. Human participants The study population will include 52 male/female patients with paroxysmal AF, aged 21 or older, including all races. Since AF is extremely rare in patients less than 21 years old, this age limit is not expected to affect the overall results.  Inclusion Criteria: 1. Male and female patients older than 21 year old  2. Paroxysmal AF  Exclusion Criteria: 
10  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
1. Left ventricular dysfunction (Left ventricular ejection fraction <40%) 2. Significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant valvular diseases)  3. Recent (<6 months) stroke or myocardial infarction  4. Severe heart failure (NYHA IV) 5. Left atrial dilatation (>55mm) 6. Recurrent vaso-vagal syncopal episodes 7. Unilateral or bilateral vagotomy 8. Pregnancy or breast feeding 9. Sick sinus syndrome, 2nd or 3rd degree AV block, bifascicular block or prolonged (PR>300ms) 1st degree AV block.  2.  Identify sources of research material in the form of specimens, records or data. The research information will consist of the AF burden and serum inflammatory cytokines at each time point specified in the protocol (see Figure 4).  3.  Describe plans for recruitment and consent procedures to be followed. a.  Describe the location where consent is most likely to take place (will consent be obtained while an inpatient, in the ER/ICU, will consents be mailed with follow-up meeting to discuss the consent, etc.). Patients will be recruited from the inpatient services and outpatient clinics of the University of Oklahoma Health Sciences Center. All candidate subjects will have the purpose of the study explained to them, including the benefits and risks and options, prior to scheduled ablation procedure, will be asked to read the consent form, and after questions have been answered, will be asked to participate. Finally, they will be asked to sign the consent form.  b. Describe provisions for recruiting non-English speaking participants. Only English-speaking persons will be recruited. Non-English-speaking adults constitute less than 1% of the patients referred for ablation. c.   Describe measures to decrease coercion of participants (allowing adequate time to review the consent, avoid recruitment of your own private patients â€“ or have a qualified assistant assist with the consent of these individuals, avoid recruiting employees or staff to serve as controls, etc.).  Patients will have adequate time to review the consent. Recruiting of employees or staff by the principal investigator will be avoided.  3. Describe risks and assess likelihood and seriousness.  
tVNS
tVNS
tVNS

tVNS

13  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
the poor success and potential side effects of the currently available treatment options, an alternative approach such as the one tested in this study (tragus stimulation) may benefit a large number of patients in Oklahoma.  H.  Data and Safety Monitoring Plan  1.  Describe the Data and Safety Monitoring Plan (DSMP) An independent Data Safety Monitoring Board (DSMB) committee consisting of 2 cardiologists and 1 statistician will monitor the study. All adverse events will be reported to the DSMB committee. The committee will review recruitment and retention data, protocol adherence data, data quality, and safety data every 6 months a. reporting mechanisms for adverse events to the IRB, FDA, and NIH Clinical staff will track from patient report, physical assessments and documentation of clinical emergencies, adverse events according to federally published grading (0=no adverse event; 1=mild; 2=moderate; 3=severe and undesirable adverse events; 4=life threatening/disabling; or 5=death) and attribution (1=unrelated; 2=unlikely; 3=possible; 4=probable; 5=definite) scales. Clinical staff will report findings to the Investigator, who will then advise the IRB, NIH and FDA as indicated. Given the mild risk nature of the study, composite reports will be reviewed every ten patients to assure that untoward events do not occur systematically, and dropout cases will be reviewed singly to learn whether further inquiry or modifications should be made to improve study implementation.  b. adverse event (AE) grading 0=no AE; 1=mild; 2=moderate; 3=severe and undesirable AE; 4=life threatening/disabling; or 5=death  c. plan for unanticipated AE reporting Unanticipated AE will be reported to the IRB. d. plan for annual reporting of AEs Use of IRB forms for reporting. Our data sheet will have a column detaining any AEs that might occur. e. interim efficacy analysis where appropriate Not indicated. 2. Describe the Data and Safety Monitoring Board (DSMB) that will be responsible for monitoring the study. 
14  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
x Institutional studies provide: a. Chair, members  Dr. Ralph Lazzara Dr. Nicole Tran Dr. Ding Kai b. Frequency of safety reviews After each study      I. Literature sited 1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952. 2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375. 3. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009;119(4):606-618. 4. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534-1539. 5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125. 6. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313-320. 7. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906. 8. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122(23):2368-2377. 9. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57(2):160-166. 10. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol. 2002;1(8):477-482. 
15  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
11. Uthman BM, Reichl AM, Dean JC, et al. Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year observation. Neurology. 2004;63(6):1124-1126. 12. Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008;10(9):884-891. 13. De Ferrari GM, Crijns HJ, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011;32(7):847-855. 14. Li S, Scherlag BJ, Yu L, et al. Low-level vagosympathetic stimulation: a paradox and potential new modality for the treatment of focal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009;2(6):645-651. 15. Sheng X, Scherlag BJ, Yu L, et al. Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation. J Am Coll Cardiol. 2011;57(5):563-571. 16. Yu L, Scherlag BJ, Li S, et al. Low-level vagosympathetic nerve stimulation inhibits atrial fibrillation inducibility: direct evidence by neural recordings from intrinsic cardiac ganglia. J Cardiovasc Electrophysiol. 2011;22(4):455-463. 17. Yu L, Scherlag BJ, Sha Y, et al. Interactions between atrial electrical remodeling and autonomic remodeling: how to break the vicious cycle. Heart Rhythm. 2012;9(5):804-809. 18. Sha Y, Scherlag BJ, Yu L, et al. Low-level right vagal stimulation: anticholinergic and antiadrenergic effects. J Cardiovasc Electrophysiol. 2011;22(10):1147-1153. 19. Shen MJ, Shinohara T, Park HW, et al. Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation. 2011;123(20):2204-2212. 20. Huston JM, Tracey KJ. The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J Intern Med. 2011;269(1):45-53. 21. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458-462. 22. Bernik TR, Friedman SG, Ochani M, et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 2002;36(6):1231-1236. 23. Mioni C, Bazzani C, Giuliani D, et al. Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. Crit Care Med. 2005;33(11):2621-2628. 24. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384-388. 25. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med. 2011;17(10):556-563. 26. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006-3010. 27. Saba S, Janczewski AM, Baker LC, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific 
16  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol. 2005;289(4):H1456-1467. 28. Fallgatter AJ, Neuhauser B, Herrmann MJ, et al. Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm. 2003;110(12):1437-1443. 29. Yu L, Scherlag BJ, Li S, et al. Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a noninvasive approach to treat the initial phase of atrial fibrillation. Heart Rhythm. 2013;10(3):428-435. 30. Stavrakis S, Humphrey MB, Scherlag BJ, et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J Am Coll Cardiol. 2015;65(9):867-875. 31. Clancy JA, Mary DA, Witte KK, Greenwood JP, Deuchars SA, Deuchars J. Non-invasive Vagus Nerve Stimulation in Healthy Humans Reduces Sympathetic Nerve Activity. Brain Stimul. 2014;7(6):871-877. 32. Gidron Y, Kupper N, Kwaijtaal M, Winter J, Denollet J. Vagus-brain communication in atherosclerosis-related inflammation: a neuroimmunomodulation perspective of CAD. Atherosclerosis. 2007;195(2):e1-9. 33. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm. 2002;11(2):87-93. 34. Rosenberg MA, Samuel M, Thosani A, Zimetbaum PJ. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol. 2013;36(3):328-333. 35. Peuker ET, Filler TJ. The nerve supply of the human auricle. Clin Anat. 2002;15(1):35-37. 36. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2014;64(21):e1-76. 37. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-1065. 38. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med. 2007;13(3-4):178-184. 39. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004;25(5):363-370. 40. Marsland AL, Gianaros PJ, Prather AA, Jennings JR, Neumann SA, Manuck SB. Stimulated production of proinflammatory cytokines covaries inversely with heart rate variability. Psychosom Med. 2007;69(8):709-716. 41. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104(24):2886-2891. 
17  
      IRB NUMBER: 5631 IRB APPROVAL DATE: 07/10/2017   
42. Kreuzer PM, Landgrebe M, Husser O, et al. Transcutaneous vagus nerve stimulation: retrospective assessment of cardiac safety in a pilot study. Frontiers in psychiatry. 2012;3:70. 43. Busch V, Zeman F, Heckel A, Menne F, Ellrich J, Eichhammer P. The effect of transcutaneous vagus nerve stimulation on pain perception--an experimental study. Brain stimulation. 2013;6(2):202-209. 44. Kreuzer PM, Landgrebe M, Resch M, et al. Feasibility, safety and efficacy of transcutaneous vagus nerve stimulation in chronic tinnitus: an open pilot study. Brain stimulation. 2014;7(5):740-747. 45. Lehtimaki J, Hyvarinen P, Ylikoski M, et al. Transcutaneous vagus nerve stimulation in tinnitus: a pilot study. Acta Otolaryngol. 2013;133(4):378-382. 46. Kraus T, Hosl K, Kiess O, Schanze A, Kornhuber J, Forster C. BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation. Journal of neural transmission. 2007;114(11):1485-1493. 47. Cristancho P, Cristancho MA, Baltuch GH, Thase ME, O'Reardon JP. Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year. The Journal of clinical psychiatry. 2011;72(10):1376-1382. 48. Stefan H, Kreiselmeyer G, Kerling F, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012;53(7):e115-118.  